Multi-functional polymeric nanoparticles for tumour-targeted drug delivery

Expert Opinion on Drug Delivery
Lilian E van Vlerken, Mansoor Amiji

Abstract

The use of nanoparticles as drug delivery vehicles for anticancer therapeutics has great potential to revolutionise the future of cancer therapy. As tumour architecture causes nanoparticles to preferentially accumulate at the tumour site, their use as drug delivery vectors results in the localisation of a greater amount of the drug load at the tumour site; thus improving cancer therapy and reducing the harmful nonspecific side effects of chemotherapeutics. In addition, formulation of these nanoparticles with imaging contrast agents provides a very efficient system for cancer diagnostics. Given the exhaustive possibilities available to polymeric nanoparticle chemistry, research has quickly been directed at multi-functional nanoparticles, combining tumour targeting, tumour therapy and tumour imaging in an all-in-one system, providing a useful multi-modal approach in the battle against cancer. This review will discuss the properties of nanoparticles that allow for such multiple functionality, as well as recent scientific advances in the area of multi-functional nanoparticles for cancer therapeutics.

References

Apr 1, 1976·Journal of Applied Physiology·M L LandsmanW G Zijlstra
Jan 1, 1992·Acta Oncologica·A L Harris, D Hochhauser
Aug 3, 1988·Biochimica Et Biophysica Acta·G BradleyV Ling
Apr 1, 1995·Biotechnology and Applied Biochemistry·M ShinkaiT Kobayashi
Feb 1, 1994·Molecular and Chemical Neuropathology·R F Barth, A H Soloway
Jun 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D R FerryD J Kerr
Nov 1, 1996·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·G P RaaphorstC E Ng
Jun 13, 1998·The Journal of Experimental Medicine·N AltanS M Simon
Aug 15, 1998·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·S MorelM R Gasco
Jan 12, 1999·Critical Reviews in Therapeutic Drug Carrier Systems·J A Reddy, P S Low
Mar 4, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·H MaedaK Hori
Jul 13, 2000·Nutrition and Cancer·M CascanteL G Boros
Oct 4, 2000·Journal of Pharmaceutical Sciences·B StellaP Couvreur
Apr 3, 2001·Nature Biotechnology·R Weissleder
Jul 12, 2001·Journal of Colloid and Interface Science·S. A. Gómez-LoperaA. V. Delgado
Dec 26, 2001·Chemical Reviews·K E UhrichK M Shakesheff
Jan 5, 2002·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Futoshi ShikataYoshinobu Fukumori
Feb 19, 2002·Current Opinion in Biotechnology·Warren C W ChanShuming Nie
Mar 21, 2002·Nature Reviews. Cancer·Michael M GottesmanSusan E Bates
Mar 28, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jennifer TranRobert S Kerbel
Aug 16, 2002·Pharmaceutical Research·Goldie Kaul, Mansoor Amiji
Sep 3, 2002·Advanced Drug Delivery Reviews·Irène BriggerPatrick Couvreur
Oct 5, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·Cristina FonsecaRogério Gaspar
Nov 16, 2002·International Journal of Pharmaceutics·Jugminder S Chawla, Mansoor M Amiji
Jan 16, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Anupama PotineniMansoor M Amiji
Apr 25, 2003·Cancer Control : Journal of the Moffitt Cancer Center·Hilary Thomas, Helen M Coley
May 2, 2003·Journal of the American Chemical Society·Akin AkincRobert Langer
May 3, 2003·Journal of Experimental Therapeutics & Oncology·John A Kellen
May 17, 2003·Nature Reviews. Drug Discovery·Ruth Duncan
Jun 20, 2003·The New England Journal of Medicine·Mukesh G HarisinghaniRalph Weissleder
Nov 5, 2003·Proceedings of the National Academy of Sciences of the United States of America·L R HirschJ L West
Nov 26, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·C VauthierP Couvreur
Dec 5, 2003·Analytical Biochemistry·Alyona SukhanovaIgor Nabiev
Jan 31, 2004·Technology in Cancer Research & Treatment·Christopher LooRebekah Drezek
Mar 17, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Moses O OyewumiRussell J Mumper

❮ Previous
Next ❯

Citations

Aug 3, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Alka MadaanHrishikesh Kulkarni
Feb 15, 2012·Journal of Medicinal Chemistry·Si WangMaurizio Pellecchia
Jan 20, 2012·Chemical Communications : Chem Comm·Se Won BaeJong-In Hong
Sep 27, 2006·Cancer Biotherapy & Radiopharmaceuticals·Huguette Albrecht, Sally J DeNardo
Nov 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Si WangMaurizio Pellecchia
Feb 14, 2007·Journal of Nanobiotechnology·Angela O ChoiDusica Maysinger
Apr 19, 2007·Journal of Nanobiotechnology·Savita BishtAnirban Maitra
Nov 30, 2011·Journal of Nanobiotechnology·Anil Mahapatro, Dinesh K Singh
Sep 2, 2008·Biological & Pharmaceutical Bulletin·Dong-Myung KimHo-Jun Kim
May 19, 2011·International Journal of Nanomedicine·Massoud AmanlouMehdi Abbasi
Aug 29, 2012·International Journal of Nanomedicine·Nasimudeen R JabirMohammad A Kamal
Aug 21, 2012·Therapeutic Delivery·Mariacristina GagliardiAngelo Bifone
Jul 28, 2012·Therapeutic Delivery·Erik C DreadenMostafa A El-Sayed
Mar 19, 2014·The European Physical Journal. E, Soft Matter·Gavin A Buxton
Nov 30, 2013·Pharmaceutical Research·B Maria AlphonsaR Jayakumar
Sep 10, 2014·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Ufuk GunduzGungor Gunduz
Oct 8, 2014·Nature Reviews. Drug Discovery·Vladimir P Torchilin
Jul 31, 2012·ACS Applied Materials & Interfaces·Zehedina KhatunYong-Kyu Lee
Nov 21, 2012·Langmuir : the ACS Journal of Surfaces and Colloids·Siva Sai Krishna DasaLiaohai Chen
May 1, 2007·Nanobiotechnology : the Journal at the Intersection of Nanotechnology, Molecular Biology, and Biomedical Sciences·Jie LuFuyuhiko Tamanoi
May 14, 2014·International Journal of Molecular Sciences·Alle MadhusudhanSurya S Singh
May 19, 2011·Expert Opinion on Drug Delivery·Krassimira Yoncheva, Georgi Momekov
Jul 15, 2015·Journal of Drug Targeting·Smita Pawar, Pradeep Vavia
Feb 23, 2013·Expert Opinion on Drug Delivery·Mohammad AliAmit Kumar Dinda
Jun 23, 2009·Expert Opinion on Drug Delivery·Jill M Stukel, Michael R Caplan
Aug 18, 2012·Expert Opinion on Drug Delivery·Sohail AkhterRobbert J Kok
Jan 12, 2013·Artificial Cells, Nanomedicine, and Biotechnology·Min-Soo KimSung-Joo Hwang
Jan 18, 2008·Journal of Pharmaceutical Sciences·Ales Prokop, Jeffrey M Davidson
Aug 16, 2011·International Journal of Pharmaceutics·Thomas PerrierJean-Pierre Benoît
Jun 28, 2011·Advanced Drug Delivery Reviews·Melgardt M de VilliersYuri M Lvov
Apr 19, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Lara MilaneMansoor Amiji
Mar 19, 2011·Drug Discovery Today·Murali Mohan YallapuSubhash C Chauhan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved